Celldex posts investor presentation highlighting barzolvolimab late-stage chronic urticaria program milestones
CLDX•Other pipeline milestones
- Phase 3 ColdU/SD study initiated in Dec. 2025.
- Phase 2 atopic dermatitis study is fully enrolled, with topline data expected late 2026.
- CDX-622, a bispecific targeting TSLP and SCF, posted positive Phase 1 healthy-volunteer data.
- A Phase 1 asthma proof-of-mechanism study started in Jan. 2026.
Late-stage barzolvolimab program update
Celldex outlined a late-stage immunology pipeline centered on barzolvolimab, a KIT antagonist antibody targeting mast cells.
- Phase 3 CSU program enrollment was completed 6 months ahead of guidance.
- Topline data are expected in Sept./Oct. 2026.
- The topline readout is set to cover both EMBARQ-CSU trials, the Week 12 primary endpoint, and safety through Week 24.
